TargetMol

Oprozomib

Product Code:
 
TAR-T6041
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6041-1mg1mg£118.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6041-5mg5mg£176.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6041-1mL1 mL * 10 mM (in DMSO)£193.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6041-10mg10mg£211.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6041-25mg25mg£321.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6041-50mg50mg£446.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Oprozomib (ONX 0912) , an inhibitor for CT-L activity of 20S proteasome β5?IC50=36 nM?/LMP7?IC50=82 nM?, is orally bioavailable. Oprozomib also has potential antineoplastic activity.
CAS:
935888-69-0
Formula:
C25H32N4O7S
Molecular Weight:
532.61
Pathway:
Autophagy; Ubiquitination; Proteases/Proteasome
Purity:
0.9987
SMILES:
s1c(ncc1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)[C@@]1(OC1)C)Cc1ccccc1)COC)COC)C
Target:
Proteasome; Autophagy

References

Chen X, Chen Y, Ou Y, et al. Bortezomib inhibits NLRP3 inflammasome activation and NF-?B pathway to reduce psoriatic inflammation. Biochemical Pharmacology. 2022, 206: 115326. Chauhan D, et al. Blood, 2010, 116(23), 4906-4915. Muchamuel T, Nat Med, 2009, 15(7), 781-787. Chen X, Chen Y, Ou Y, et al. Bortezomib inhibits NLRP3 inflammasome activation and NF-?B pathway to reduce psoriatic inflammation. Biochemical Pharmacology. 2022, 206: 115326. Zhou HJ, et al. J Med Chem, 2009, 52(9), 3028-3038.